With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.136992-95-5,Benzo[d]oxazol-7-amine,as a common compound, the synthetic route is as follows.
A mixture of benzooxazol-7-amine (135 mg, 1.01 mmol, Astrazeneca, PCT Appl. WO2003053960), 2.4-dichloropyrimidine (150 mg, 1.01 mmol), DBU (0.197 ml, 1.32 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (58 mg, 0.1 mmol, also named xantphos) and tris(dibenzylideneacetone)dipalladium(0) (58 mg, 0.1 mmol, also named Pd2dba3) in dioxane (3 ml) under argon was irradiated in a Personal Chemistry EMRYS Optimizer EXP microwave synthesisor at 110 C. for 10 minutes. After cooling and evaporation of the solvents, the residue was dissolved in DCM and purified by chromatography on silica gel (eluant: 30% to 60% EtOAc in petroleum ether) to give N-(2-chloropyrimidin-4-yl)benzooxazol-7-amine (88 mg, 35%) as a beige solid. Mass spectrum: MH+ 247
As the paragraph descriping shows that 136992-95-5 is playing an increasingly important role.
Reference£º
Patent; AstraZeneca AB; US2011/46108; (2011); A1;,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem